Shots:

• The first patient has been dosed in a P-I study of HLX04-O conducting in patients with wAMD. The primary objective of the study is to evaluate the safety & tolerability of HLX04-O in 6-12 patients with wAMD
• The secondary objective of the study is to evaluate the PK profiles of HLX04-O after intravitreal injection
• In Oct’2020- Henlius signed co-development and exclusive license agreement with Essex. The companies plan to conduct clinical trials of HLX04-O in China- Australia- EU- and the US- and apply marketing authorization in different countries and regions across the globe

Click here to read full press release/ article | Ref: Henlius | Image: nature